Welcome!

News Feed Item

MD Anderson Announces Collaboration With Johnson & Johnson Innovation On Cancer Immunotherapy

HOUSTON, Jan. 21, 2014 /PRNewswire-USNewswire/ -- The University of Texas MD Anderson Cancer Center  will collaborate with Johnson & Johnson Innovation, LLC, and its affiliate Janssen Biotech, Inc., to develop immunology-based cancer treatments through the MD Anderson Moon Shots Program immunotherapy platform.

"The strengths of both organizations in the rapidly growing field of cancer immunotherapy can exploit opportunities to develop more effective treatments for cancer patients," said Jim Allison, Ph.D., chair of Immunology and executive director of the immunotherapy platform.  "We look forward to collaborating with Johnson & Johnson Innovation."

MD Anderson's Moon Shots Program is an ambitious effort to dramatically reduce cancer deaths, starting with six moon shots that target eight cancers and are backed by several platforms - infrastructure, technology or expertise - that support research efforts.

The 3-year translational research agreement brings together the scientific and clinical capabilities of MD Anderson and Johnson & Johnson Innovation and Janssen Biotech, Inc., to develop rational combination therapies and personalized medicine approaches as well as to identify new treatment opportunities.

The collaboration with Johnson & Johnson Innovation is the second such arrangement made through the moon shots immunotherapy platform. Only a few companies will be selected to become partners to the platform.

"Our new collaborations with pharmaceutical and biotech companies through our immunotherapy platform are different from traditional agreements, because they allow both parties to work on any project they deem appropriate without additional budgets," said Ferran Prat, Ph.D., J.D., MD Anderson's vice president of strategic industry ventures.

"We provide our pharma and biotech collaborators access to state-of-the-art facilities, novel research protocols for clinical trials open to our large and diverse patient population, and an opportunity to work with leaders in the field of immunotherapy," Prat said.

Prat said this collaboration will explore oncology focus areas of interest to Janssen Biotech, Inc.

Allison's basic science research on T cell biology led to an entirely new method of treating cancer called immune checkpoint blockade, which blocks receptors on the surface of T cells that tumors use to turn off immune attack.

Allison created an antibody to one such checkpoint, called CTLA-4, and worked in its development as the drug ipilimumab (Yervoy), the first drug of its kind and also the first to be approved by the U.S. Food and Drug Administration for late-stage melanoma. More than 20 percent of melanoma patients given the drug develop long-lasting remissions for five years and longer.

In December, the journal Science designated cancer immunotherapy as its 2013 Breakthrough of the Year, noting Allison's leadership in the field, The Economist named Allison winner of its 2013 Innovations Award for Biosciences and he received a $3 million Breakthrough Prize in Life Sciences from the foundation of the same name launched last year by internet and social media entrepreneurs. 

MD Anderson's immunotherapy platform has enhanced and increased the institution's capabilities in expertise, technology and techniques since Allison's arrival in November of 2012.

Patrick Hwu, M.D., chair of Melanoma Medical Oncology is co-director of the platform.  Translational physician-scientist Padmanee Sharma M.D., Ph.D., associate professor of Genitourinary Medical Oncology, is scientific director.

MD Anderson has invested $40 million in the platform, including philanthropic funds and a $10 million Established Investigator grant from the Cancer Prevention and Research Institute of Texas to recruit Allison from Memorial Sloan-Kettering Cancer Center in New York. Allison holds MD Anderson's Vivian L. Smith Distinguished Chair in Immunology.

Since approval of ipilimumab in 2011, additional immune checkpoint receptors and drugs to target them have been discovered and are in clinical trials. At MD Anderson, clinical trials of ipilimumab and other agents target melanoma, lymphoma, lung, breast, gastric and prostate cancers, with more planned.

MD Anderson researchers also are working on a variety of ways to enhance T cell attack on cancer cells. For example, one method involves harvesting a patient's own cancer-targeting T cells, expanding their number in the lab, then reinfusing them in the patient.  Another involves customizing a patient's T cells via gene transfer to more efficiently attack tumors and then giving them back to patients.  Both methods are in clinical trials.

Therapeutic vaccine development also is under way for melanoma, lymphoma and breast cancer.

About MD Anderson

The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. MD Anderson is one of only 41 comprehensive cancer centers designated by the National Cancer Institute (NCI). For ten of the past 12 years, including 2013, MD Anderson has ranked No. 1 in cancer care in "Best Hospitals," a survey published annually in U.S. News & World Report. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).

Get MD Anderson News Via RSS  Follow MD Anderson News on Twitter

This news release was issued on behalf of Newswise(TM). For more information, visit http://www.newswise.com.

SOURCE The University of Texas M. D. Anderson Cancer Center

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
IoT is rapidly changing the way enterprises are using data to improve business decision-making. In order to derive business value, organizations must unlock insights from the data gathered and then act on these. In their session at @ThingsExpo, Eric Hoffman, Vice President at EastBanc Technologies, and Peter Shashkin, Head of Development Department at EastBanc Technologies, discussed how one organization leveraged IoT, cloud technology and data analysis to improve customer experiences and effici...
"We are an all-flash array storage provider but our focus has been on VM-aware storage specifically for virtualized applications," stated Dhiraj Sehgal of Tintri in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Fact is, enterprises have significant legacy voice infrastructure that’s costly to replace with pure IP solutions. How can we bring this analog infrastructure into our shiny new cloud applications? There are proven methods to bind both legacy voice applications and traditional PSTN audio into cloud-based applications and services at a carrier scale. Some of the most successful implementations leverage WebRTC, WebSockets, SIP and other open source technologies. In his session at @ThingsExpo, Da...
The cloud competition for database hosts is fierce. How do you evaluate a cloud provider for your database platform? In his session at 18th Cloud Expo, Chris Presley, a Solutions Architect at Pythian, gave users a checklist of considerations when choosing a provider. Chris Presley is a Solutions Architect at Pythian. He loves order – making him a premier Microsoft SQL Server expert. Not only has he programmed and administered SQL Server, but he has also shared his expertise and passion with b...
"IoT is going to be a huge industry with a lot of value for end users, for industries, for consumers, for manufacturers. How can we use cloud to effectively manage IoT applications," stated Ian Khan, Innovation & Marketing Manager at Solgeniakhela, in this SYS-CON.tv interview at @ThingsExpo, held November 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA.
As data explodes in quantity, importance and from new sources, the need for managing and protecting data residing across physical, virtual, and cloud environments grow with it. Managing data includes protecting it, indexing and classifying it for true, long-term management, compliance and E-Discovery. Commvault can ensure this with a single pane of glass solution – whether in a private cloud, a Service Provider delivered public cloud or a hybrid cloud environment – across the heterogeneous enter...
Without a clear strategy for cost control and an architecture designed with cloud services in mind, costs and operational performance can quickly get out of control. To avoid multiple architectural redesigns requires extensive thought and planning. Boundary (now part of BMC) launched a new public-facing multi-tenant high resolution monitoring service on Amazon AWS two years ago, facing challenges and learning best practices in the early days of the new service. In his session at 19th Cloud Exp...
The cloud promises new levels of agility and cost-savings for Big Data, data warehousing and analytics. But it’s challenging to understand all the options – from IaaS and PaaS to newer services like HaaS (Hadoop as a Service) and BDaaS (Big Data as a Service). In her session at @BigDataExpo at @ThingsExpo, Hannah Smalltree, a director at Cazena, provided an educational overview of emerging “as-a-service” options for Big Data in the cloud. This is critical background for IT and data professionals...
Today we can collect lots and lots of performance data. We build beautiful dashboards and even have fancy query languages to access and transform the data. Still performance data is a secret language only a couple of people understand. The more business becomes digital the more stakeholders are interested in this data including how it relates to business. Some of these people have never used a monitoring tool before. They have a question on their mind like “How is my application doing” but no id...
@GonzalezCarmen has been ranked the Number One Influencer and @ThingsExpo has been named the Number One Brand in the “M2M 2016: Top 100 Influencers and Brands” by Onalytica. Onalytica analyzed tweets over the last 6 months mentioning the keywords M2M OR “Machine to Machine.” They then identified the top 100 most influential brands and individuals leading the discussion on Twitter.
What happens when the different parts of a vehicle become smarter than the vehicle itself? As we move toward the era of smart everything, hundreds of entities in a vehicle that communicate with each other, the vehicle and external systems create a need for identity orchestration so that all entities work as a conglomerate. Much like an orchestra without a conductor, without the ability to secure, control, and connect the link between a vehicle’s head unit, devices, and systems and to manage the ...
More and more brands have jumped on the IoT bandwagon. We have an excess of wearables – activity trackers, smartwatches, smart glasses and sneakers, and more that track seemingly endless datapoints. However, most consumers have no idea what “IoT” means. Creating more wearables that track data shouldn't be the aim of brands; delivering meaningful, tangible relevance to their users should be. We're in a period in which the IoT pendulum is still swinging. Initially, it swung toward "smart for smar...
In an era of historic innovation fueled by unprecedented access to data and technology, the low cost and risk of entering new markets has leveled the playing field for business. Today, any ambitious innovator can easily introduce a new application or product that can reinvent business models and transform the client experience. In their Day 2 Keynote at 19th Cloud Expo, Mercer Rowe, IBM Vice President of Strategic Alliances, and Raejeanne Skillern, Intel Vice President of Data Center Group and G...
"We are a modern development application platform and we have a suite of products that allow you to application release automation, we do version control, and we do application life cycle management," explained Flint Brenton, CEO of CollabNet, in this SYS-CON.tv interview at DevOps at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Information technology is an industry that has always experienced change, and the dramatic change sweeping across the industry today could not be truthfully described as the first time we've seen such widespread change impacting customer investments. However, the rate of the change, and the potential outcomes from today's digital transformation has the distinct potential to separate the industry into two camps: Organizations that see the change coming, embrace it, and successful leverage it; and...